[1] |
SUNG H, FERLAY J, SIEGEL R L,et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249. DOI:10.3322/caac.21660.
|
[2] |
PIRLOG R, CISMARU A, NUTU A,et al. Field cancerization in NSCLC:a new perspective on MicroRNAs in macrophage polarization[J]. Int J Mol Sci,2021,22(2):E746. DOI:10.3390/ijms22020746.
|
[3] |
WANG R X, CHEN C Y, KANG W B,et al. SNHG9 was upregulated in NSCLC and associated with DDP-resistance and poor prognosis of NSCLC patients[J]. Am J Transl Res,2020,12(8):4456-4466.
|
[4] |
CHAN B A, HUGHES B G. Targeted therapy for non-small cell lung cancer:current standards and the promise of the future[J]. Transl Lung Cancer Res,2015,4(1):36-54. DOI:10.3978/j.issn.2218-6751.2014.05.01.
|
[5] |
NORMANDO S R, CRUZ F M, DEL GIGLIO A. Cumulative meta-analysis of epidermal growth factor receptor-tyrosine kinase inhibitors as first-line therapy in metastatic non-small-cell lung cancer[J]. Anticancer Drugs,2015,26(9):995-1003. DOI:10.1097/CAD.0000000000000268.
|
[6] |
SHI Y K, WANG L, HAN B H,et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE):a phase 3,open-label,randomized study[J]. Ann Oncol,2017,28(10):2443-2450. DOI:10.1093/annonc/mdx359.
|
[7] |
WANG J, WANG B C, CHU H L,et al. Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations[J]. Onco Targets Ther,2016,9:3711-3726. DOI:10.2147/OTT.S106399.
|
[8] |
刘丽娅,朱颖,涂长玲,等. 小分子抗血管生成药物在非小细胞肺癌中的研究进展[J]. 现代肿瘤医学,2020,28(4):663-667.
|
[9] |
许子宜,李峻岭. 晚期非小细胞肺癌抗血管生成药物的联合治疗模式[J]. 中国肺癌杂志,2021,24(5):357-364.
|
[10] |
YAMAMOTO N, SETO T, NISHIO M,et al. Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer:survival follow-up results of the randomized JO25567 study[J]. Lung Cancer,2021,151:20-24. DOI:10.1016/j.lungcan.2020.11.020.
|
[11] |
STINCHCOMBE T E, JÄNNE P A, WANG X F,et al. Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non-small cell lung cancer:a phase 2 randomized clinical trial[J]. JAMA Oncol,2019,5(10):1448-1455. DOI:10.1001/jamaoncol.2019.1847.
|
[12] |
ZHAO H Y, YAO W X, MIN X H,et al. Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant NSCLC:the phase III ACTIVE study (CTONG1706)[J]. J Thorac Oncol,2021,16(9):1533-1546. DOI:10.1016/j.jtho.2021.05.006.
|
[13] |
SAITO H, FUKUHARA T, FURUYA N,et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026):interim analysis of an open-label,randomised,multicentre,phase 3 trial[J]. Lancet Oncol,2019,20(5):625-635. DOI:10.1016/S1470-2045(19)30035-X.
|
[14] |
KATO T, SETO T, NISHIO M,et al. Erlotinib plus bevacizumab phase ll study in patients with advanced non-small-cell lung cancer (JO25567):updated safety results[J]. Drug Saf,2018,41(2):229-237. DOI:10.1007/s40264-017-0596-0.
|
[15] |
KITAGAWA C, MORI M, ICHIKI M,et al. Gefitinib plus bevacizumab vs. gefitinib alone for EGFR mutant non-squamous non-small cell lung cancer[J]. In Vivo,2019,33(2):477-482. DOI:10.21873/invivo.11498.
|
[16] |
NAKAGAWA K, GARON E B, SETO T,et al. Ramucirumab plus erlotinib in patients with untreated,EGFR-mutated,advanced non-small-cell lung cancer (RELAY):a randomised,double-blind,placebo-controlled,phase 3 trial[J]. Lancet Oncol,2019,20(12):1655-1669. DOI:10.1016/S1470-2045(19)30634-5.
|
[17] |
SETO T, KATO T, NISHIO M,et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567):an open-label,randomised,multicentre,phase 2 study[J]. Lancet Oncol,2014,15(11):1236-1244. DOI:10.1016/S1470-2045(14)70381-X.
|
[18] |
ZHOU Q, WU Y L, CHENG Y,et al. CTONG 1509:Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC[J]. Ann Oncol,2019,30:v603. DOI:10.1093/annonc/mdz260.002.
|
[19] |
高琳,虞永峰,陆舜. EGFR靶向治疗的现状、机遇和挑战[J]. 中国肿瘤临床,2021,48(10):495-500.
|
[20] |
梁文华,黎才琛,梁恒瑞,等. 表皮生长因子受体敏感突变肺癌靶向治疗原发耐药的机制及临床对策[J]. 中国全科医学,2021,24(8):901-916,922.
|
[21] |
AISNER D L, SHOLL L M, BERRY L D,et al. The impact of smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations-the lung cancer mutation consortium (LCMC2)[J]. Clin Cancer Res,2018,24(5):1038-1047. DOI:10.1158/1078-0432.CCR-17-2289.
|
[22] |
SALDAÑA-RIVERA L, BELLO M, MÉNDEZ-LUNA D. Structural insight into the binding mechanism of ATP to EGFR and L858R,and T790M and L858R/T790 mutants[J]. J Biomol Struct Dyn,2019,37(17):4671-4684. DOI:10.1080/07391102.2018.1558112.
|
[23] |
HSU K H, HUANG Y H, TSENG J S,et al. High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients[J]. Lung Cancer,2019,127:37-43. DOI:10.1016/j.lungcan.2018.11.021.
|
[24] |
LANGER C, SORIA J C. The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer[J]. Clin Lung Cancer,2010,11(2):82-90. DOI:10.3816/CLC.2010.n.011.
|
[25] |
OLSSON A K, DIMBERG A, KREUGER J,et al. VEGF receptor signalling - in control of vascular function[J]. Nat Rev Mol Cell Biol,2006,7(5):359-371. DOI:10.1038/nrm1911.
|
[26] |
TABERNERO J. The role of VEGF and EGFR inhibition:implications for combining anti-VEGF and anti-EGFR agents[J]. Mol Cancer Res,2007,5(3):203-220. DOI:10.1158/1541-7786.MCR-06-0404.
|
[27] |
JACKSON A L, ZHOU B, KIM W Y. HIF,hypoxia and the role of angiogenesis in non-small cell lung cancer[J]. Expert Opin Ther Targets,2010,14(10):1047-1057. DOI:10.1517/14728222.2010.511617.
|
[28] |
LE X N, NILSSON M, GOLDMAN J,et al. Dual EGFR-VEGF pathway inhibition:a promising strategy for patients with EGFR-mutant NSCLC[J]. J Thorac Oncol,2021,16(2):205-215. DOI:10.1016/j.jtho.2020.10.006.
|
[29] |
VILORIA-PETIT A, CROMBET T, JOTHY S,et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo:a role for altered tumor angiogenesis[J]. Cancer Res,2001,61(13):5090-5101.
|
[30] |
FENG P H, CHEN K Y, HUANG Y C,et al. Bevacizumab reduces S100A9-positive MDSCs linked to intracranial control in patients with EGFR-mutant lung adenocarcinoma[J]. J Thorac Oncol,2018,13(7):958-967. DOI:10.1016/j.jtho.2018.03.032.
|
[31] |
JIANG T, ZHANG Y C, LI X F,et al. EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases[J]. Eur J Cancer,2019,121:98-108. DOI:10.1016/j.ejca.2019.08.021.
|
[32] |
凌丰宇,李明,陈青娟,等. 贝伐珠单抗联合第一代表皮生长因子受体-酪氨酸激酶抑制剂一线治疗EGFR基因突变阳性晚期非小细胞肺癌的Meta分析[J]. 肿瘤,2020,40(5):339-347,354.
|
[33] |
胥昕怡,占美,张晟肇,等. 厄洛替尼联合贝伐珠单抗治疗EGFR突变晚期非小细胞肺癌患者的有效性和安全性的Meta分析[J]. 中国医院药学杂志,2021,41(16):1658-1664. DOI:10.13286/j.1001-5213.2021.16.11.
|
[34] |
DENG Z J, QIN Y, LIU Y M,et al. Role of antiangiogenic agents combined with EGFR tyrosine kinase inhibitors in treatment-naive lung cancer:a meta-analysis[J]. Clin Lung Cancer,2021,22(1):e70-83. DOI:10.1016/j.cllc.2020.08.005.
|